• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should Device Recalls Require Action From Boston Scientific Stock Investors?

    Simply Wall St·09/08/2026 14:22:51
    Listen to the news
    • Boston Scientific has initiated multiple voluntary recalls covering more than 225,000 ENROUTE neuroprotection and OverStitch Suture Cinch devices after FDA classifications as Class I and Class II events, with issues centered on sheath tip separation and failure to deploy or cut sutures as intended across broad global distribution.
    • These simultaneous recalls concentrate operational pressure on Boston Scientific's quality systems, recall logistics and potential remediation costs at the same time that management is investing heavily in new therapies and global expansion.
    • Given the Class I neuroprotection recall and its global scope, the next step is to see how this episode reshapes Boston Scientific's investment narrative.

    Scan how Boston Scientific's recall experience compares with other device makers facing product risk by reviewing our hand picked 83 resilient stocks with low risk scores in the same broader market.

    Boston Scientific Investment Narrative Recap

    To own Boston Scientific, you need to believe the device portfolio in cardiovascular and MedSurg can keep pulling in procedure volume, even as tariffs, reimbursement pressure and competition chip away at pricing. The immediate swing factor is execution on high value therapies like FARAPULSE and WATCHMAN, which underpin much of the medium term earnings story. The recent ENROUTE and OverStitch recalls concentrate attention on quality systems. If they stay contained and are resolved through letters and field action, the bigger near term issue likely remains cost headwinds and integration risk around recent acquisitions.

    The Class I recall of the ENROUTE Transcarotid Neuroprotection System and ENROUTE Plus looks most important right now. These products sit alongside Silk Road related stroke prevention efforts that many investors view as part of Boston Scientific’s long term structural opportunity. An arterial sheath tip problem on more than 160,000 units worldwide tests manufacturing controls, post market surveillance and hospital relationships. Execution here matters because the same organization is responsible for scaling FARAPULSE, WATCHMAN and ASC related rollouts that analysts expect to support mid single digit revenue growth.

    Yet there is one operational wrinkle tied to these recalls that is easy to gloss over until you consider …

    Read the full Boston Scientific narrative to see the case behind these numbers.

    Boston Scientific's current narrative points to forecast revenue of US$24.6b and expected earnings of US$4.4b by 2029. This outlook is based on analyst assumptions of 5.4% yearly revenue growth and an earnings increase of about US$0.7b from current earnings of US$3.7b.

    Boston Scientific's forecasts point to a $62.69 fair value versus the $47.80 share price, indicating a 31% upside to its current price that could narrow quickly.

    NYSE:BSX 1-Year Stock Price Chart
    NYSE:BSX 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most optimistic analysts focus on Boston Scientific’s acquisition push as the key catalyst. Before these recalls, the bullish camp was modeling about US$28.0b of revenue and US$5.5b of earnings by 2029. That is a much richer story than consensus, and it may be revisited as investors reassess quality and integration risk after this news.

    To see how other investors value Boston Scientific, compare its current price with the 6 other fair value estimates for Boston Scientific.

    Reach Your Own Conclusion

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking for more Boston Scientific style investment ideas?

    Once you have a view on Boston Scientific, it can help to widen the lens and compare it with other businesses that fit different risk and return profiles using the Simply Wall St Screener.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.